Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

EPP
XLP

Interventions

DRUG: MT-7117

Sponsor

Tanabe Pharma America, Inc.